Factor | 2011 Guideline | 2018 Guideline |
Age | ≥50 years | Any |
Stage | T1-2 N0 | Any stage provided intent is to treat the whole breast without an additional field to cover the regional lymph nodes |
Chemotherapy | None | Any chemotherapy |
Dose homogeneity | ±7% in the central axis | Volume of breast tissue receiving >105% of the prescription dose should be minimized regardless of dose-fractionation |
Do you want to add Medilib to your home screen?